Company intelligence / Profile preview
Vistagen Therapeutics
South San Francisco, California, United Statesvistagen.com ↗
- Ownership
- Public · VTGN
- Employees
- ~39
- Development stage
- Phase 3
01
Overview
Vistagen’s lead candidate fasedienol (PH94B) has shown positive results in the PALISADE Phase 3 program for acute treatment of social anxiety disorder. The company’s pipeline includes five clinical-stage pherine product candidates and an oral prodrug targeting CNS disorders. AV-101 has demonstrated safety and potential efficacy in preclinical and early clinical studies for neuropathic pain and other CNS indications. Fasedienol has not shown abuse potential or physical dependence signals to date.
- Therapeutic areas
- Women's HealthPsychiatryNeurology
- Modalities
- Pherine nasal sprays (intranasal neuroactive agents)small molecule oral prodrugs
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
No specific partnerships disclosed as current but seeking strategic collaborations for AV‑101 development/commercialization
04
Financials
- Market cap
- $10.6M
- Total revenue
- $1.5M
- Enterprise value
- $-20.3M
Beyond the preview
Go deeper on Vistagen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vistagen Therapeutics.